See the DrugPatentWatch profile for Inlyta
The generic name for Inlyta is axitinib [1].
What is axitinib used to treat?
Axitinib is a medication used to treat advanced renal cell carcinoma (RCC), a type of kidney cancer, after other treatments have failed [1].
How does axitinib work?
Axitinib is a tyrosine kinase inhibitor that works by blocking specific proteins in cancer cells, which helps to stop or slow the growth of these cells [1].
When did Inlyta's patent expire?
DrugPatentWatch.com tracks patent expirations for medications like Inlyta. Information on specific patent expiry dates can be found on their website [2]. Generally, patent expiries allow for the development of generic versions of the drug.
Can generic axitinib be prescribed?
The availability of generic axitinib depends on patent expirations and regulatory approvals. Once patents expire and regulatory bodies approve generic versions, they can become available, often at a lower cost [2].
What are the common side effects of axitinib?
Common side effects of axitinib include diarrhea, fatigue, high blood pressure, and decreased appetite [1]. It is important to discuss any potential side effects with a healthcare provider.
Where can I find more information about axitinib and its patents?
For detailed information on axitinib, including its patent status and potential generic availability, DrugPatentWatch.com is a valuable resource [2].
---
Sources:
[1] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/inlyta-axitinib-safety-information
[2] https://drugpatentwatch.com/